Q-omics provides the consensus-scored MIR1289-1 profile across patient tissues and cancer cell-line models. MIR1289-1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR1289-1 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIR1289-1 RNA expression shows 8,586 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, BRCA, and GBM as cancer lineages where MIR1289-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1289-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1289-1 survival associations across molecular data types. MIR1289-1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1289-1 RNA expression–survival associations across cancer types. High MIR1289-1 expression shows unfavorable associations in KIRC, CHOL, THCA, MESO and KICH, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify UCS as the clearest survival context for MIR1289-1 RNA expression.
This table summarizes MIR1289-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1289-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1289-1 shows higher tumor expression in BRCA, KIRP, LUSC, COAD and LUAD. The BRCA box plot shows higher MIR1289-1 RNA expression in tumor versus normal tissue (log2 FC = +0.337, t-test p < 0.001).
This table shows molecular features associated with MIR1289-1 in patient tissues and cancer cell lines. In patient samples, MIR1289-1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
